Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax's Hepatitis B Vaccine Shows More Rapid Immunogenicity, More Durable Protective Response Than Engerix-B in Phase 2 Clinical Trial
Dynavax's Hepatitis B Vaccine Shows More Rapid Immunogenicity, More Durable Protective Response Than Engerix-B in Phase 2 Clinical Trial 100% Protective Response Sustained More Than One Year Later After Two-Dose Regimen of Dynavax's ISS-based Vaccine BERKELEY, Calif., Nov 1, 2004
View HTML
Toggle Summary Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast
Dynavax Announces Third Quarter 2004 Financial Results Conference Call and Webcast BERKELEY, Calif., Oct 27, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that Company executives will hold a conference call to discuss Dynavax's third quarter 2004 financial
View HTML
Toggle Summary Dynavax to Present Data on Phase 2 Clinical Trial of Hepatitis B Vaccine at ICAAC
Dynavax to Present Data on Phase 2 Clinical Trial of Hepatitis B Vaccine at ICAAC BERKELEY, Calif., Oct 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2 clinical trial of its ISS-based Hepatitis B
View HTML
Toggle Summary Dynavax Establishes Collaboration With Riken Institute for Development of Cedar Allergy Therapeutics for Japanese Market
Dynavax Establishes Collaboration With Riken Institute for Development of Cedar Allergy Therapeutics for Japanese Market BERKELEY, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company developing treatments for allergy,
View HTML
Toggle Summary Dynavax to Webcast Presentation at UBS Global Life Sciences Conference on Thursday, September 30, 2004
Dynavax to Webcast Presentation at UBS Global Life Sciences Conference on Thursday, September 30, 2004 BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, M.D., President and CEO, will present an overview of the company at the UBS
View HTML
Toggle Summary Dynavax Appoints Jane Green Vice President, Corporate Communications
Dynavax Appoints Jane Green Vice President, Corporate Communications BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Jane Green, Ph.D., as Vice President, Corporate Communications. Dr.
View HTML
Toggle Summary Dynavax Announces Completion of Enrollment of Phase II/III Hepatitis B Prophylactic Vaccine Trial
Dynavax Announces Completion of Enrollment of Phase II/III Hepatitis B Prophylactic Vaccine Trial BERKELEY, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that it has completed enrollment and administered the first round of immunizations
View HTML
Toggle Summary Dynavax Names Timothy Henn, Vice President, Finance & Administration
Dynavax Names Timothy Henn, Vice President, Finance & Administration BERKELEY, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of Timothy Henn, to the position of Vice President, Finance and Administration. Mr.
View HTML
Toggle Summary Dynavax Reports 2004 Second Quarter Results
Dynavax Reports 2004 Second Quarter Results BERKELEY, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious
View HTML
Toggle Summary Dynavax Asthma Data Supports Advancing Program to Efficacy Trials
Dynavax Asthma Data Supports Advancing Program to Efficacy Trials Safety Confirmed; Biological Activity Indicates Reprogramming Of Immune System BERKELEY, Calif., July 28 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery,
View HTML